| Publicerad idag 10:36

UBS lifts its Genmab target by 58 per cent as all twelve houses go up

Text: Redaktion | [email protected]
Genmab A/S – Consensus Analysis 18 November 2026 | BioStock Analytics
Consensus Analysis · 18 November 2026

UBS lifts its Genmab target by 58 per cent as all twelve houses go up

This Consensus Analysis of Genmab includes the analyst houses that published a target within 90 days prior to 17 November 2026.

Twelve houses are included and all twelve raised their target. Ten did so before the Q3 report of 5 November, and two have published since.

The median target of 4,450 DKK is 27.1 per cent above the close of 3,502.00 DKK on 17 November 2026, and the mean of 4,204 DKK is 20.1 per cent above it.

Stock price
3,502.00DKK
Mean target
4,204DKK
Upside on the mean
+20.1%
Included targets
12
Median target
4,450DKK
Upside on the median
+27.1%
01 – Consensus at a glance

Snapshot as of 17 November 2026

Target range
3,200–4,900 DKK
Market cap
215 bn DKK
P/E (TTM)
48.3x
at 3,502.00 DKK
02 – Analyst panel

All public targets

Fifteen houses have published targets or ratings for Genmab in the last twelve months. Out of these, twelve presented an updated target within the time window for this analysis, spanning from 90 days prior to 17 November. These twelve are the basis for the aggregates in this Consensus Analysis.

Sydbank lowered its rating to Hold on 29 October without a published target. Handelsbanken and Bernstein last published in March and February. These three sit below the divider and are left out of the aggregates.

BNP Paribas, Kempen and Rothschild & Co Redburn also cover the share, but are left out because their latest target could not be matched to a dated public notice.

HousePreviousTargetRec.Last
UBS [6]3,100▲4,900Buy16 Nov
SEB [7] pre-report3,175▲4,600Buy29 Oct
TD Cowen [8] pre-report3,435▲4,526Buy29 Oct
Barclays [9] pre-report3,400▲4,500Overweight29 Oct
Goldman Sachs [10]4,450▲4,500Buy6 Nov
Nordea [11] pre-report3,200▲4,500Buy29 Oct
Bank of America [12] pre-report4,200▲4,400Buy2 Nov
DNB Carnegie [13] pre-report3,100▲4,100Hold29 Oct
Deutsche Bank [14] pre-report3,500▲4,000Buy29 Oct
Jyske Bank [15,17] pre-report2,925▲3,725Sell29 Oct
J.P. Morgan [16,17] pre-report2,050▲3,500Overweight26 Oct
Jefferies [18] pre-report2,900▲3,200Buy26 Oct
Sydbank [19]–no targetHold29 Oct
Handelsbanken [20]2,200▲2,220Buy3 Mar
Bernstein [21]1,015▲1,400Underperform23 Feb

pre-report Target set before the Q3 report of 5 November 2026. With only two targets published since the report, the aggregates use the 90 days to 17 November 2026 and the row is included.

Barclays and J.P. Morgan published Overweight, which normalises to Buy. Bernstein published Underperform, which normalises to Sell. Targets published only on the US-listed ADR in dollars are not carried.

Scroll the table sideways to see every column.

03 – Target distribution

Where the panel sits

Of the twelve included targets, ten sit above the close of 3,502.00 DKK on 17 November 2026 and two sit below it.

Seven of the twelve lie between 4,400 and 4,900 DKK, and the full range runs from 3,200 to 4,900 DKK.

Included target prices by house, with the share price, median and mean 3,200 3,400 3,600 3,800 4,000 4,200 4,400 4,600 4,800 5,000 DKK Median 4,450 Mean 4,204 Share price 3,502.00 3,200 Jefferies 3,500 J.P. Morgan 3,725 Jyske Bank 4,000 Deutsche Bank 4,100 DNB Carnegie 4,400 Bank of America 4,500 Barclays 4,500 Goldman Sachs 4,500 Nordea 4,526 TD Cowen 4,600 SEB 4,900 UBS Buy Hold Sell
04 – Recommendation breakdown

Buy · Hold · Sell

Ten of the twelve included analyst houses rate the share Buy. DNB Carnegie rates it Hold and Jyske Bank Sell.

The percentages are rounded and sum to 99 per cent.

Buy
10 (83%)
Hold
1 (8%)
Sell
1 (8%)
Promotion
BioVal by BioStock: sum-of-the-parts valuations for Nordic biotech.
05 – Period catalysts

Dated events behind the panel

  • 5 Oct 2026
    Epcoritamab with R-CHOP improves progression-free survival in phase III
    Genmab and AbbVie reported that the EPCORE DLBCL-2 trial of epcoritamab with R-CHOP showed a statistically significant improvement in progression-free survival in newly diagnosed diffuse large B-cell lymphoma. [2]
  • 23 Oct 2026
    Rina-S phase III RAINFOL-02 meets progression-free and overall survival
    In platinum-resistant ovarian cancer, Rina-S cut the risk of disease progression or death by 71 per cent against investigator's choice chemotherapy in the intent-to-treat population (HR 0.29). The trial also met its key secondary endpoint of overall survival. [3]
  • 28 Oct 2026
    Petosemtamab phase III LiGeR-HN1 meets both primary endpoints
    At the first interim analysis, petosemtamab with pembrolizumab halved the risk of death against pembrolizumab alone in first-line PD-L1-positive recurrent or metastatic head and neck cancer (HR 0.50) and improved the objective response rate. [4]
  • 5 Nov 2026
    Q3 report: revenue up 22 per cent, guidance kept
    Revenue for the first nine months was 3,238 million dollars against 2,662 million a year earlier. Diluted net profit per share was 11.23 dollars against 14.90 dollars. The 2026 guidance published on 6 August was maintained. [1]
06 – Key signals

Three takeaways from the panel

The two lowest targets were published before the head and neck readout

Jefferies at 3,200 DKK and J.P. Morgan at 3,500 DKK published on 26 October, after the RAINFOL-02 results and two days before LiGeR-HN1.

The other ten included targets were set from 29 October onward and lie between 3,725 and 4,900 DKK. Their mean is 4,375 DKK, 24.9 per cent above the close.

The Sell rating came with a higher target

Jyske Bank lowered Genmab to Sell on 29 October with a target of 3,725 DKK, 6.4 per cent above the close. Its previous target was 2,925 DKK. [17]

DNB Carnegie lowered Genmab to Hold the same day with a target of 4,100 DKK, up from 3,100 DKK and 17.1 per cent above the close.

Two houses have published after the Q3 report

Goldman Sachs added 50 DKK to its target on 6 November, a rise of 1.1 per cent.

UBS raised its target by 58.1 per cent on 16 November, to 4,900 DKK from 3,100 DKK. Its previous target dated from 14 October, before the RAINFOL-02 and LiGeR-HN1 readouts. [22]

Promotion
BioVal analysis: Saniona, SAN2668. Read the analysis.
07 – References

Numbered sources

  1. Genmab interim report for the nine months ended 30 September 2026, company announcement no. 45 – 5 Nov 2026, GlobeNewswire (PDF); revenue, diluted net profit per share for the nine months of 2026 and 2025 and for 2025, shares at 30 September 2026 (p. 5) and treasury shares held on that date (p. 38), the USD/DKK rate assumed in the 2026 guidance, and the post-quarter trial results
  2. Genmab and AbbVie announce epcoritamab in combination with R-CHOP demonstrates statistically significant improvement in progression-free survival in patients with newly diagnosed DLBCL – 5 Oct 2026, GlobeNewswire
  3. Genmab announces rinatabart sesutecan (Rina-S) demonstrates statistically significant improvement in progression-free survival and overall survival in patients with platinum-resistant ovarian cancer – 23 Oct 2026, GlobeNewswire
  4. Genmab announces statistically significant, clinically meaningful improvement in overall survival and objective response with petosemtamab combination at first interim analysis in first-line R/M patients with PD-L1+ head and neck cancer – 28 Oct 2026, GlobeNewswire
  5. Genmab closing price of 3,502.00 DKK on Nasdaq Copenhagen – 17 Nov 2026, Nasdaq Copenhagen, read 17 Nov 2026
  6. UBS raises its target price for Genmab to 4,900 DKK (3,100), reiterates Buy – 16 Nov 2026, Finwire via Placera, Swedish
  7. SEB raises its target price for Genmab to 4,600 DKK (3,175), reiterates Buy – 29 Oct 2026, Finwire via Placera, Swedish
  8. TD Cowen raises its target price for Genmab to 4,526 DKK (3,435), reiterates Buy – 29 Oct 2026, Finwire via Placera, Swedish
  9. Barclays raises its target price for Genmab to 4,500 DKK (3,400), reiterates Overweight – 29 Oct 2026, Finwire via Placera, Swedish
  10. Goldman Sachs raises its target price for Genmab to 4,500 DKK (4,450), reiterates Buy – 6 Nov 2026, Finwire via Placera, Swedish
  11. Nordea raises its target price for Genmab to 4,500 DKK (3,200), reiterates Buy – 29 Oct 2026, Finwire via Placera, Swedish
  12. Bank of America raises its target price for Genmab to 4,400 DKK (4,200), reiterates Buy – 2 Nov 2026, Finwire via Placera, Swedish
  13. DNB Carnegie lowers Genmab to Hold (Buy), target price 4,100 DKK (3,100) – 29 Oct 2026, Finwire via Placera, Swedish
  14. Deutsche Bank raises its target price for Genmab to 4,000 DKK (3,500), reiterates Buy – 29 Oct 2026, Finwire via Placera, Swedish
  15. Jyske Bank lowers Genmab to Sell (Hold), target price 3,725 DKK – 29 Oct 2026, Finwire via Placera, Swedish
  16. J.P. Morgan raises Genmab to Overweight (Neutral), target price 3,500 DKK – 26 Oct 2026, Finwire via Placera, Swedish
  17. Target price raises after strong study data for Rina-S: J.P. Morgan 3,500 DKK (2,050), Jyske Bank 2,925 DKK (2,350) and other houses – 27 Oct 2026, Nyhetsbyrån Direkt via Placera, Swedish; previous targets for J.P. Morgan and Jyske Bank
  18. Jefferies raises its target price for Genmab to 3,200 DKK (2,900), reiterates Buy – 26 Oct 2026, Finwire via Placera, Swedish
  19. Sydbank lowers Genmab to Hold (Buy) – 29 Oct 2026, Finwire via Placera, Swedish
  20. Handelsbanken raises its target price for Genmab to 2,220 DKK (2,200), reiterates Buy – 3 Mar 2026, Finwire via Placera, Swedish
  21. Bernstein raises its target price for Genmab to 1,400 DKK (1,015), reiterates Underperform – 23 Feb 2026, Finwire via Placera, Swedish
  22. UBS raises its target price for Genmab to 3,100 DKK (2,700), reiterates Buy – 14 Oct 2026, Finwire via Placera, Swedish
08 – Method and disclaimers

How the report was compiled

Selection. Each row in the panel is taken from its own dated notice, listed individually in the references. A house whose latest target could not be matched to a dated notice is left out rather than carried on an unverified figure. Sell-side houses only; independent research sold to end investors is outside the panel. Targets published only on the US-listed ADR in dollars are not carried. The aggregates normally use targets published after the issuer's most recent interim report. Two houses published after the Q3 report of 5 November 2026, so the aggregates use every target set in the 90 days to 17 November 2026: twelve houses, ten of them marked pre-report. Sydbank, which published a rating without a target, and Handelsbanken and Bernstein, whose latest targets are older than 90 days, are listed below the divider and are not in the aggregates.

Price and valuation basis. Consensus is referenced against the closing price of 3,502.00 DKK on Nasdaq Copenhagen on 17 November 2026. [5] Market capitalisation uses 61,494,537 shares: the 62,405,855 shares the Q3 report gives for 30 September 2026, less the 911,318 treasury shares Genmab held on that date. [1] Genmab reports in US dollars, so the price-earnings ratio converts the close at 6.2 DKK per dollar, the rate the company's 2026 guidance assumes, giving 564.84 dollars. That is a planning assumption and not a market rate on the snapshot date, and it is the same basis as the August 2026 report. The earnings are trailing twelve months of diluted net profit per share: 15.37 dollars for 2025, less 14.90 for the first nine months of 2025, plus 11.23 for the first nine months of 2026, or 11.70 dollars. [1] At 6.0 DKK per dollar the ratio would be 49.9x, and at 6.4 it would be 46.8x.

Ratings. Buy, Overweight and Outperform normalise to Buy; Hold, Neutral and Market Perform to Hold; Sell, Underweight and Underperform to Sell. The recommendation breakdown counts the included houses at their latest rating.

Nothing in this report constitutes investment advice or a recommendation to buy or sell securities.
Read offline

Take this analysis with you

A branded consensus report on Genmab, ready to share or print.

Download PDF
Genmab A/S · 18 November 2026
BioStock Analytics BioStock Analytics – Consensus Analysis
Genmab A/S · GMAB · 18 November 2026